Eroom's Law: Why Biotech Money Isn't Buying More Cures
Despite a fourfold increase in longevity biotech investment, the success rate for new drugs remains trapped in the single digits. This paradox, known as Eroom's…
Henrik Mägi
·
Oct 31, 2026 • 16:00